Articles tagged with Oncology
Researchers at NTU Singapore and Oxford University have discovered a mechanism by which cells identify and repair highly toxic DNA damage, known as DPCs, that cause cancer, neurodegeneration, and premature ageing. The study reveals how SPRTN, a key repair enzyme, selectively targets DPC lesions, increasing its activity 67-fold.
A retrospective cohort study found that COVID-19 booster vaccinations significantly protected against severe COVID-19, but uptake was low. Interventions are needed to increase COVID-19 vaccine uptake among high-risk populations with cancer.
A new study published in JAMA Network Open found no statistical relationship between pathologic complete response (pCR) and overall survival in rectal cancer patients. This challenges the FDA's use of pCR as a surrogate endpoint for drug approval, which may lead to treatments being fast-tracked without evidence of improved long-term su...
Researchers successfully treated a patient with a rare IDH2-mutant brainstem astrocytoma using temozolomide and radiation, resulting in significant tumor shrinkage and improved hearing. The patient's unique genetic profile was identified through magnetic resonance spectroscopy and surgical biopsy, allowing for targeted treatment.
The inaugural ESMO Targeted Anticancer Therapies (TAT) Asia Congress 2025 will convene a diverse group of stakeholders to foster collaboration and accelerate the development of innovative cancer therapies. The congress aims to become a catalyst for global collaboration and innovation in oncology.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
A study of 62,839 people diagnosed with non-metastatic prostate cancer in Sweden found that those treated according to NCCN Guidelines were likely to survive their cancer for their remaining life-expectancy. Those with low- and intermediate-risk cancer were six times more likely to die of other causes than prostate cancer.
The revised guidelines incorporate the latest clinical advances in graft-versus-host disease prophylaxis, expanded donor options and search strategies. The updated guidelines aim to enhance transplant outcomes for patients with blood cancers and disorders.
Researchers have identified a hidden molecular mechanism involving two proteins that allows tumors to resist treatment. A new gelatin-based nanoparticle has been developed to shut down both proteins simultaneously, showing promising results in early studies with mice.
A study published in The International Journal of Cancer found that children born by planned C-section have a higher risk of developing acute lymphoblastic leukaemia (ALL) later in life. The risk was 21% higher in children born by planned C-section compared to those born vaginally.
Researchers at Fujita Health University discovered benzaldehyde's mechanism to halt therapy-resistant pancreatic cancer growth and spread. Benzaldehyde prevents key interactions that enable cancer cells' survival and treatment resistance.
A new study by the NIH found that hormone therapy may alter breast cancer risk in women under 55. Women treated with unopposed estrogen hormone therapy were less likely to develop breast cancer, while those using estrogen plus progestin hormone therapy were more likely to develop the disease.
Michael Karin, renowned for his work on chronic inflammation and cancer, will lead the Center for Metabolic and Liver Diseases at Sanford Burnham Prebys. He aims to develop new treatments for metabolic and liver diseases, which affect millions of patients worldwide.
A new study reveals that SETD1B plays a critical role in supporting the growth of aggressive acute myeloid leukemia (AML) cells, particularly in those with FLT3-ITD mutations. By targeting SETD1B, researchers believe it may be possible to develop more effective treatments.
The new NCCN Guidelines Navigator tool offers an interactive platform for accessing evidence-based guidelines, facilitating easier searching and navigation. The initiative aims to improve patient care and outcomes by providing healthcare professionals with up-to-date recommendations.
The Association for Molecular Pathology (AMP) has announced the election results for 2026-2027 leadership positions, including President-Elect Yassmine M.N. Akkari and Secretary-Treasurer Jonathan A. Nowak. The newly elected leaders will drive AMP's mission to advance molecular diagnostics.
A new study reveals that cancer survivors experiencing food insecurity have a 28% increased risk of death compared to those who are food secure. The research, published in JAMA Health Forum, analyzed data from over 5,000 respondents and found that food insecurity was linked to higher all-cause mortality rates.
JMIR Publications' portfolio of journals now includes 21 titles with a Journal Impact Factor. Several journals saw significant increases in impact factor, including JMIR Medical Education, which debuted with a score of 12.5, securing the top-ranked journal spot in its category.
Emerging research highlights the pivotal role of circular RNAs in disease progression, influencing tumor proliferation, metastasis, immune evasion, and drug resistance. Specific circRNAs have been identified as key players in HCC progression, affecting crucial signaling pathways like PI3K/Akt, Wnt/β-catenin, and NF-κB.
The review explores the epigenetic regulatory network of lncRNAs in hepatocellular carcinoma, highlighting DNA methylation, histone modifications, RNA methylation, and microRNAs. These mechanisms drive liver cancer progression, offering insights for diagnostic and therapeutic strategies.
IGF2BP1 binds to methylated mRNA, stabilizing oncogenic transcripts and promoting cancer progression. Elevated expression of IGF2BP1 correlates with poor prognosis and therapy resistance in multiple cancers.
TsRNAs emerge as promising biomarkers for a wide range of diseases, particularly cancers. These non-coding RNA fragments exhibit remarkable stability in diverse body fluids and show disease-specific expression patterns.
ASTRO welcomes Karen Davis as its first Vice President of Business Development and Marketing, leading the organization's business growth strategy. Davis will focus on public- and private-sector partnerships to advance ASTRO's mission and broaden its impact on cancer care.
The Princess Máxima Center has implemented whole genome sequencing as the standard of care for children with cancer, enabling precise diagnosis and tailored treatment. This comprehensive approach also provides valuable data for developing new treatments and researching childhood cancer development.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Breast cancer's metabolic reprogramming holds novel treatment avenues, targeting glycolysis, glutamine, and lipid metabolism to exploit dependencies. Emerging strategies aim to enhance immunotherapy by modulating metabolic pathways.
Experts from the National Comprehensive Cancer Network (NCCN) and African Cancer Coalition gathered in Nairobi, Kenya to update NCCN Clinical Practice Guidelines in Oncology for Sub-Saharan Africa. The meeting aimed to improve cancer care in the region by sharing evidence-based recommendations.
Researchers have discovered a novel cell-clearance pathway linked to diseases such as Chediak-Higashi Syndrome, which affects immune system function. The study used CRISPR/Cas9 gene-editing technology and live imaging to characterize this pathway and identify key genes involved.
Researchers found that it took 13 years for cervical cancer screenings to halve among women over 65, and even longer for prostate cancer screenings to decrease significantly. The study emphasizes the need for more effective tracking mechanisms to identify and reduce inappropriate screening practices.
A pilot study found that exercising during chemotherapy can increase the number of immune cells fighting cancer, including CD8+ T cells and natural killer cells. The exercise programme improved patients' aerobic fitness, leading to stronger immune responses inside tumours.
A new study found a sharp increase in appendix cancer incidence rates for those born after 1945, particularly among Generation X and Millennials. The researchers estimated age-specific incidence rates of appendiceal adenocarcinoma per 100,000 persons between 1975 and 2019.
Researchers have developed a model that uses terahertz scattering to identify structural tissue changes in diseases like cancer and burn injuries. The approach shows promise for early detection and characterization of disease-related tissue features.
The Dresden research team developed an autonomous AI agent for precision medicine that can process multimodal data and have reasoning capabilities. The AI agent reached correct clinical conclusions in 91% of cases and accurately cited relevant oncology guidelines in over 75% of its responses.
A cohort study found that obesity in childhood cancer survivors is linked to an increased risk of developing multiple subsequent neoplasms. Conversely, high levels of physical activity are associated with a reduced risk of these cancers.
Recent advances in tissue-agnostic cancer drugs have resulted in highly effective treatments, but few are approved for children. Oncologists argue that these drugs should be licensed for all ages due to their effectiveness and fewer side effects. The researchers suggest that age-agnostic approvals could be made through analyzing electr...
The Phase 1 study of EBC-129 has shown encouraging signs of efficacy in heavily pre-treated pancreatic ductal adenocarcinoma patients, with an overall response rate of 25% and disease control rate of 87.5%. The drug also demonstrated a manageable safety profile, with no major treatment-related adverse events.
Combining immunotherapy drug dostarlimab with standard chemotherapy improved survival and reduced symptoms in patients with advanced endometrial cancer. Patients lived up to 5.5 months longer with fewer side effects, outweighing risks.
Rapid advances in cancer treatment have improved long-term survival rates, but current resources and models of care in Canada do not meet the changing needs of people with cancer. The authors propose solutions such as reducing unnecessary surveillance and establishing interdisciplinary specialty clinics.
A global clinical trial led by Irish cancer specialist Prof. Patrick Forde shows that immunotherapy with chemotherapy before lung cancer surgery reduces the risk of cancer returning and improves long-term survival. The study found that patients who received immunotherapy plus chemotherapy had improved outcomes compared to those who rec...
A study found slightly lower adenoma detection rates in adults aged 45-49 compared to older groups, consistent with previous evaluations of screening colonoscopies. The study's findings suggest that the lowered screening age may have a beneficial effect on colon cancer prevention.
A circulating tumor DNA-based blood test demonstrated acceptable accuracy for colorectal cancer detection in an average-risk population. However, it struggled to detect advanced precancerous lesions, highlighting the need for further improvements.
Researchers found that e-cigarette warnings are effective in discouraging vaping, with health harm warnings being more effective than addiction warnings. The analysis included 22,549 participants and showed no negative unintended consequences, such as encouraging people to smoke cigarettes instead of vaping.
A recent study published in JAMA Oncology suggests that modern phase 3 oncology trials often prioritize overall survival over quality of life, which may not accurately reflect patient needs. Future trial designs should focus on improving overall survival and quality-of-life outcomes to better represent patient experiences.
A study found that fewer than half of U.S. adults are aware of the link between alcohol and cancer, highlighting a need for increased awareness and action. The findings emphasize the importance of reducing the alcohol-related cancer burden in the US.
Researchers have identified FAM111B as a promising candidate for glioma treatment. The study found that FAM111B overexpression enhances glioma malignancy through the PI3K/AKT pathway, providing a novel avenue for therapeutic intervention.
Researchers identified four areas of support needed for adolescent and young adult cancer patients: school accommodations, extracurricular activities, academic trajectory, and social connections. Supporting scholastic performance can help mitigate negative impacts on mental health and financial security.
The Experimental Drug Development Centre's EBC-129, an antibody-drug conjugate targeting pancreatic cancer, has received FDA fast track designation. The treatment is undergoing Phase 1 clinical trials and aims to provide new treatment options for patients with solid tumours.
The National Comprehensive Cancer Network (NCCN) honors individuals who champion access to high-quality, patient-centered cancer care. This year's recipients include Drs. Nadeem Abu-Rustum and Louis Nabors for their excellence in engagement and dedication to shaping cancer treatment recommendations.
Researchers from Mayo Clinic Comprehensive Cancer Center will present practice-changing studies on chemotherapy approaches, AI applications in oncology, and new therapies for breast and melanoma. The event will feature 59 abstracts highlighting advancements in cancer care.
Researchers examined baseline characteristics of adolescent and young adult (AYA) cancer survivors seen in oncology primary care clinic, finding high rates of comorbidities and cardiovascular disease. They also studied the overexpression of IRAK4 protein in acute myeloid leukemia (AML) cells, with potential implications for treatment.
The University of Houston has launched a $3M Cancer Immunotherapy Biomarker Core to accelerate early diagnosis and treatment response in cancer. The core will offer comprehensive targeted proteomic cancer biomarker screens, enabling researchers to identify better biomarkers for cancer.
Dana-Farber researchers have identified several promising interventions for breast and colorectal cancer, including a potential new treatment approach for stage III deficient DNA mismatch repair colon cancer and improved strategies for treating rare and aggressive forms of brain lymphoma. The findings will be presented at the 2025 Annu...
The European Society for Medical Oncology (ESMO) has released the latest version of the ESMO-MCBS scale, which measures the clinical benefit of cancer treatments. The new version incorporates 13 critical amendments to improve evaluation and accuracy, with a focus on patient preferences and toxicity annotations.
A study published in PNAS reveals that colorectal cancer cells utilize a protein called TBX3, which regulates embryo development, to contribute to their aggressiveness and metastasis. The discovery opens up possibilities for developing targeted therapies to prevent tumor cell spread.
Researchers developed an artificial intelligence technique that detects DNA fragments in patient blood to monitor treatment response. The ARTEMIS-DELFI approach was found to be more effective and simpler than existing methods, allowing for quicker identification of patients who are not responding to therapy.
A randomized controlled trial found that additional imaging techniques such as fast MRI and contrast mammography can detect early-stage cancers in women with dense breasts that were missed by mammograms. The study showed a cancer detection rate of 1.7% for fast MRI and 1.9% for contrast mammography, compared to 0.4% for ultrasound.
A new study published in Blood Cancer Discovery found that certain gene mutations and the maturity of leukemia cells affect how patients respond to venetoclax and hypomethylating agents. Researchers identified a subtype of acute myeloid leukemia with worse outcomes, particularly those without the NPM1 mutation.
A team of researchers at Baylor College of Medicine identified six flavonoids that kill bladder cancer cells, including compounds that cause DNA damage and disrupt energy supply. The study uses Cell Painting technology to analyze large-scale drug screening data sets on a standard desktop computer.
A new liquid biopsy blood test called HPV-DeepSeek achieved 99% sensitivity and specificity for diagnosing cancer in asymptomatic patients. The test detected fragments of the viral genome and other features in the blood, outperforming current methods in detecting HPV-associated head and neck cancers.
US survivors of adolescence and young adult cancer experience significantly worse mental health outcomes into middle age and older adulthood. Cancer clinicians should acknowledge this mental health burden and take steps to address it.